Molecular Pharmacology Program

The David Scheinberg Lab

Research

David A. Scheinberg, MD, PhD
Chair, Molecular Pharmacology Program, SKI; Director, Center for Experimental Therapeutics, MSK; Deputy Director, Sloan Kettering Institute, for Therapeutic Discovery

The overall goals of this laboratory are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes antibodies, targeted nano-devices, engineered cells, and active specific agents such vaccines. An important goal is to take these new therapies into human clinical trials for testing. Examples include a molecular nanogenerator that releases alpha particles inside cancer cells, now being tested in Phase II human trials (Blood, 2010), and a vaccine to WT1 in Phase III trials. Read full article in Science. 

We have developed targeted alpha particle therapies, targeted beta emitters, oncogenic protein peptide vaccines, humanized antibodies, each of which reached human clinical trials; More recently we have discovered TCR mimic antibodies to intracellular proteins (Science Trans. Med., 2013), (Nature Biotech., 2015), as well as prototype targeted nano-machines (Nature Nano, 2013)

Research Projects

The David Scheinberg Lab

Publications

People

David Scheinberg

David A. Scheinberg, MD, PhD

Chair, Molecular Pharmacology Program, SKI; Director, Center for Experimental Therapeutics, MSK; Deputy Director, Sloan Kettering Institute, for Therapeutic Discovery

  • Molecular Pharmacology Program Chair David Scheinberg focuses on the discovery and development of novel, specific immunotherapeutic agents and targeted nanodevices for cancer therapy.
  • MD, PhD, Johns Hopkins University School of Medicine
scheinbd@mskcc.org
Email Address
646-888-2190
Office Phone
View physician profile
Physician profile

Members

Michael Curcio

Research Assistant

Tao Dao

Senior Research Scientist

Tatyana Korontsvit

Research Assistant

Michael McDevitt
Michael R. McDevitt

Laboratory Member

Zita Aretz
Zita Aretz

Graduate Student

Christopher Bourne
Christopher Bourne

Graduate Student

Barbara de Mello
Barbara De Mello

Research Assistant

James Han

Research Associate

Heather Jones

Graduate Student

Keifer Kurtz
Keifer Kurtz

Graduate Student

Michael X. Lau
Michael X. Lau

Pediatric Hematology/Oncology Fellow

Manish Malviya
Manish Malviya

Senior Research Scientist

Sung Soo Mun

Research Assistant

Ekaterina Revskaya
Ekaterina Revskaya

Senior Research Scientist

Pedro Silberman

Graduate Student

Kristen Vogt
Kristen Vogt

Graduate Student

Lab Alumni
Emily C. Casey, BS
Emily C. Casey

Principal Scientific Communication Lead at Genentech, San Francisco, CA

Aaron Chang

Graduate Student

Freddie Escorcia
Thomas J. Gardner, PhD
Thomas J. Gardner

Research Fellow

Ron Gejman
Ron Gejman

Graduate Student

William Maguire

Graduate Student

Prabodhika Mallikaratchy, PhD
Prabodhika Mallikaratchy

Visiting Scientist

Justin J. Mulvey

Graduate Student

Andrew Scott

Research Technician

Jonathan Seideman

Graduate Student

Nicholas Veomett

Graduate Student

Carlos Villa

Graduate Student

Sam Wong

Graduate Student

Victoriya Zakhaleva, Research Technician
Victoriya Zakhaleva

Research Technician

Bryan Aristega

Research Technician

Mamadou A. Bah

Lab Rotation SEP-DEC 2020

Megan Dacek
Megan Dacek

Graduate Student

Casey Jarvis

Research Technician

Martin G. Klatt

Research Fellow

Melissa Mathias

Research Fellow

Leila Peraro

Research Scholar

Lab Affiliations

Lab News & Events

Journal Club & Photo Album

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

David A. Scheinberg discloses the following relationships and financial interests:

  • Actinium
    Intellectual Property Rights; Ownership / Equity Interests; Provision of Services
  • Arvinas, Inc
    Ownership / Equity Interests
  • Bridge Medicines
    Provision of Services (uncompensated)
  • ContraFect
    Ownership / Equity Interests
  • Ensysce Bioscience
    Ownership / Equity Interests
  • Eureka Therapeutics Inc
    Ownership / Equity Interests; Provision of Services (uncompensated)
  • Great Point Partners
    Ownership / Equity Interests; Provision of Services
  • Iovance Biotherapeutics, Inc.
    Ownership / Equity Interests
  • Lantheus Medical Imaging, Inc.
    Ownership / Equity Interests
  • OncoPep, Inc.
    Provision of Services
  • Pfizer, Inc.
    Ownership / Equity Interests; Provision of Services
  • Repertoire Immune Medicines, Inc.
    Provision of Services
  • Sapience Therapeutics, Inc.
    Fiduciary Role/Position; Ownership / Equity Interests
  • Sellas Life Science Group
    Fiduciary Role/Position; Intellectual Property Rights; Ownership / Equity Interests

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures